Kolon Group is in the biggest crisis since its foundation as the Ministry of Food and Drug Safety has revoked the license of Kolon Life Science's Invossa-KInj. Invossa has been regarded as the biggest achievement of the former group chairman Lee Woong-yeul, who used to say that he invested a thi
Kolon Life Sciences said on Jan. 14 that it has signed an agreement with Mundipharma of the United States to export 100 billion won (US$89.75 million) worth of Invossa, the world's first cell and gene therapy for osteoarthritis, to nine countries.Under the terms of the agreement, Mundipharma wil
Kolon Life Science announced on Nov. 19 that it has signed a technology export contract with multinational pharmaceutical company Mundipharma to launch Invossa-K, a cell gene therapy for osteoarthritis treatment developed by its subsidiary Kolon TissueGene, in Japan.The total contract amount is 667.
More and more Korean CEOs at multinational pharmaceutical firms in Korea are being forced to leave the company or receiving disciplinary measures from the headquarters for various reasons.CEO Hak-sun Moon at Novartis Korea which received search and seizure from the prosecution for suspicion of rebat